Salud financiera de hoja de balance de ANI Pharmaceuticals
Salud financiera controles de criterios 3/6
ANI Pharmaceuticals tiene un patrimonio de accionistas total de $430.8M y una deuda total de $625.4M, lo que sitúa su ratio deuda-patrimonio en 145.2%. Sus activos y pasivos totales son $1.3B y $856.6M respectivamente. El BAIT de ANI Pharmaceuticals es de $21.8M, por lo que su ratio de cobertura de intereses es de 1.3. Tiene efectivo e inversiones a corto plazo que ascienden a $153.3M.
Información clave
145.2%
Ratio deuda-patrimonio
US$625.36m
Deuda
| Ratio de cobertura de intereses | 1.3x |
| Efectivo | US$153.28m |
| Patrimonio | US$430.80m |
| Total pasivo | US$856.58m |
| Activos totales | US$1.29b |
Actualizaciones recientes sobre salud financiera
Here's Why ANI Pharmaceuticals (NASDAQ:ANIP) Can Manage Its Debt Responsibly
Nov 09
Is ANI Pharmaceuticals (NASDAQ:ANIP) Using Too Much Debt?
Aug 08These 4 Measures Indicate That ANI Pharmaceuticals (NASDAQ:ANIP) Is Using Debt Reasonably Well
Feb 17Does ANI Pharmaceuticals (NASDAQ:ANIP) Have A Healthy Balance Sheet?
Sep 22Does ANI Pharmaceuticals (NASDAQ:ANIP) Have A Healthy Balance Sheet?
Feb 22We Think ANI Pharmaceuticals (NASDAQ:ANIP) Has A Fair Chunk Of Debt
Oct 28Recent updates
Here's Why ANI Pharmaceuticals (NASDAQ:ANIP) Can Manage Its Debt Responsibly
Nov 09ANI Pharmaceuticals Is Acting Like It Is Being Acquired
Nov 02ANI Pharmaceuticals: A Rare GARP Stock In An Overbought Market
Oct 11There's No Escaping ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Muted Revenues
Sep 10ANI Pharmaceuticals' (NASDAQ:ANIP) Earnings Are Weaker Than They Seem
Aug 14Is ANI Pharmaceuticals (NASDAQ:ANIP) Using Too Much Debt?
Aug 08ANI Pharmaceuticals: Tezruly Just Approved, 2 More NDAs Under Review And Alimera Science Acquisition Could Triple Revenue By 2028
Aug 02Subdued Growth No Barrier To ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Price
Jun 10ANI Pharmaceuticals Is Undervalued, As Royalty Potential Is Overlooked
Jun 10These 4 Measures Indicate That ANI Pharmaceuticals (NASDAQ:ANIP) Is Using Debt Reasonably Well
Feb 17Additional Considerations Required While Assessing ANI Pharmaceuticals' (NASDAQ:ANIP) Strong Earnings
Nov 15Does ANI Pharmaceuticals (NASDAQ:ANIP) Have A Healthy Balance Sheet?
Sep 22Does ANI Pharmaceuticals (NASDAQ:ANIP) Have A Healthy Balance Sheet?
Feb 22We Think ANI Pharmaceuticals (NASDAQ:ANIP) Has A Fair Chunk Of Debt
Oct 28ANI Pharma launches generic Prochlorperazine maleate tablets
Aug 29ANI Pharmaceuticals' generic dexamethasone tablets get FDA approval
Aug 16Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($521.3M) de ANIP superan a sus pasivos a corto plazo ($189.9M).
Pasivo a largo plazo: Los activos a corto plazo ($521.3M) de ANIP no cubren sus pasivos a largo plazo ($666.6M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: La relación deuda neta-capital de ANIP (109.6%) se considera alta.
Reducción de la deuda: El ratio deuda-patrimonio de ANIP ha crecido de 91.2% a 145.2% en los últimos 5 años.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: Aunque no es rentable ANIP tiene suficiente cash runway para más de 3 años si mantiene su actual nivel positivo de flujo de caja libre.
Pronóstico de cash runway: ANIP no es rentable pero tiene suficiente cash runway para más de 3 años, debido a que el flujo de caja libre es positivo y crece un 18.5% al año.